TMCnet News
Huge Alert On: (OTCBB:IMUC) - (OTCBB:INIS) - (OTCBB:OPMG)(M2 PressWIRE Via Acquire Media NewsEdge) Rochester NY -- www.otc-advisors.com names: (OTCBB:IMUC) ImmunoCellular Therapeutics, Ltd. , (OTCBB:INIS) International Isotopes, Inc., and (OTCBB:OPMG) Options Media Group Holdings, Inc., its "Bulls Of The Day"! Visit: www.otc-advisors.com for current profiles. To feature your publicly traded company in our alerts email us at [email protected]. To sign up for our free newsletter or to be added to our Quarterly Investment Magazine visit http://www.otc-advisors.com/contact.htm Also, you can receive up to the minute stock alerts via our Twitter/Facbook page. www.twitter.com/otcadvisors or www.facebook.com/pages/OTC-ADVISORS-LLC/259891872296 ------------------------------------------------------------------------------------------------------------------------------------------------------------ Visit: www.otc-advisors.com About ImmunoCellular Therapeutics, Ltd. IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently completed a Phase I trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. The Company is planning to initiate a multicenter phase II study in the second half of 2010. The Company's "off the shelf" therapeutic vaccine product candidate (ICT-121) targeting cancer stem cells for multiple cancer indications is targeted by IMUC to enter clinical trials for glioblastoma during the second half of 2010. IMUC has entered into a research and license option deal with the Roche Group for one of the Company's monoclonal antibody product candidates for the diagnosis and treatment of ovarian cancer and multiple myeloma, which provides for potential licensing and milestone payments of $32MM and royalties if the Roche Group exercises its option and commercializes this antibody technology for multiple indications. IMUC is in pre-clinical development of another monoclonal antibody product candidate for the treatment of small cell lung cancer and pancreatic cancer, and is also evaluating its platform technology for monoclonal antibody discovery to target cancer stem cells. To learn more about IMUC, please visit www.imuc.com. News Today: LOS ANGELES, Apr 01, 2010 -- ImmunoCellular Therapeutics (OTCBB: IMUC) announced today that it has filed its Annual Report with the Securities and Exchange Commission for the period ended December 31, 2009 on Form 10-K. "During 2009 the company advanced its leading product candidates ICT-107 and ICT-121 through the release of promising data," said Manish Singh, Ph.D., President and CEO. "We look forward to commencing a Phase II clinical trial for ICT-107 and to enter clinical trials for ICT-121 during the second half of the year." Some of the fiscal 2009 and recent highlights include: Financial: -- Unqualified Audit Opinion. ImmunoCellular Therapeutics received an unqualified opinion from its independent auditor that it has sufficient capital to fund its clinical development and other operating activities for at least the next twelve months. -- Research and license option agreement. The company entered into a research and license option agreement regarding its ICT-69 antibody with Roche Group one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. -- Receipt of $10 million financial commitment. ImmunoCellular Therapeutics entered into a definitive agreement with Socius Life Sciences Capital Group, LLC. ("Socius"), under which Socius committed to purchase from time to time up to $10 million of non-convertible Preferred Stock from the Company. -- Signed key manufacturing and development agreement for ICT-121. The company entered into an agreement with Formatech, Inc. for the manufacture and development of its cancer stem cell vaccine product candidate, ICT-121, for an upcoming clinical trial. The agreement calls for Formatech to develop a formulation for ICT-121 that allows for long-term stability of the vaccine as well as suitability for intradermal injection. Scientific: -- Promising clinical results from ICT-107 Phase I trials. ICT-107, IMUC's dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer, demonstrated the ability to significantly extend the overall survival as well as tumor free survival time compared to the current standard of care. -- Identification of novel peptides to broaden applicability of the company's cancer stem cell vaccine candidate, ICT-121. The identification of these peptides enables the use of IMUC's product candidate in patients with many different HLA types. The company also filed a provisional U.S. patent application related to these findings. -- Provisional patent application. The company filed a patent application related to its ICT-109 monoclonal antibody product candidate. The application relates to what the company believes is a unique glycosidic composition of an antigen found on the surface of small cell lung cancer, colon cancer and pancreatic cancer, and covers methods for detecting, diagnosing, monitoring, staging, imaging and/or treating the cancers. -- Humanization of key antibodies. The company completed humanization of its ICT-37 and ICT-109 antibodies. Humanization is designed to increase acceptance of antibodies by host immune systems. The process was done in collaboration with Antitope, a privately held, UK based biotechnology company. -- Added key personnel. Appointed Colonel George Peoples, M.D., Dr. Constantin Ioannides, and Dr. Cohava Gelber to its Scientific Advisory Board. ------------------------------------------------------------------------------------------------------------------------------------------------------------ Visit: www.otc-advisors.com About International Isotopes Inc. International Isotopes Inc. manufactures a full range of nuclear medicine calibration and reference standards, high purity fluoride gases, and a variety of cobalt-60 products such as teletherapy sources. The Company also provides a wide selection of radioisotopes and radiochemicals for medical devices, calibration, clinical research, life sciences, and industrial applications and provides a host of analytical, measurement, recycling, and processing services on a contract basis to clients News Today IDAHO FALLS, Idaho, April 1, 2010 -- International Isotopes Inc. (OTC Bulletin Board: INIS) announces the financial results for fiscal year ended December 31, 2009. Total revenue in 2009 was $6,122,844 compared to $5,602,443 in 2008, which represents an increase of $520,401 or 9%. The overall increase in revenue was primarily the result of increases in sales in three business segments: Cobalt, Radiochemical Products, and Transportation. Cobalt Products For 2009, Cobalt Product sales (which includes bulk cobalt sales) accounted for approximately 36% of total revenue, as compared to 29% in 2008. In 2009, bulk cobalt sales account for approximately 44% of total Cobalt Product sales. Fluctuations in bulk cobalt sales can create large variations in period to period comparisons. The following table presents a year to year comparison of total revenue by segment, as well as a year to year comparison, of total revenue including and excluding bulk cobalt sales. We believe the total revenue excluding bulk cobalt sales provides meaningful information to investors because of the large period-to-period fluctuations in bulk cobalt sales. However, this information has limitations as an analytical tool and you should not consider it in isolation or as a substitute for total revenue including bulk cobalt sales. Year To % of Total Year to % of TotalDate Sales Date SalesSale of Product 2009 2009 2008 2008--------------- ---- ------------------ ----Radiochemical Products $1,714,529 28% $1,379,906 25%Cobalt Products (including bulk cobalt sales) 2,180,445 36% 1,616,020 29%Cobalt Products (excluding bulk cobalt sales) 1,215,580 24% 1,127,764 22%Nuclear Medicine Standards 1,800,935 29% 1,864,099 33%Radiological Services 239,722 4% 634,201 11%Flourine Products 878 0% 0 0%Transportation 186,335 3% 108,217 2%Corporate revenue 0 0% 0 0%---------- --------------- ---Total Segments (including bulk cobalt sales) $6,122,844 100% $5,602,443 100%---------- --------------- ---Total Segments (excluding bulk cobalt sales) 5,157,979 100% 5,114,187 100%During 2009, the Company recorded a significant write-down in cobalt inventory. This write-down totaled $740,719 and was incurred due to removing numerous targets from continued irradiation in the U.S. Department of Energy's reactor because of their level of activity. This adjustment is unusual with regard to the amount of material removed from production, is not indicative of anticipated future trends, and does not represent a reduction in planned cobalt production volumes in the future. Radiochemical Products Sales of radiochemical products accounted for approximately 28% of our total sales revenue in 2009 and increased by approximately 24% to $1,714,529, as compared to $1,379,906 in 2008. As in prior years, increased sales performance in this segment was driven largely by increases in our sales of iodine-131. Nuclear Medicine Standards Sales of nuclear medicine standards accounted for approximately 29% of our total sales revenue in 2009. Sales in this segment decreased by approximately 3% to $1,800,935 in 2009, as compared to $1,864,099 in 2008. This small decrease is believed to be the result of the nationwide recession, significant cuts in health care reimbursement, and new laws affecting outpatient imaging. Net loss for 2009, increased approximately 114% to $4,633,298, driven primarily by the Company's expenses for the proposed uranium de-conversion and fluorine extraction facility and the write-down of cobalt inventory. Gross profit decreased from 49% in 2008, to 33% in 2009, and was primarily attributable to the write-down in cobalt inventory of low activity material that was determined to have reduced marketability, and sales increases in lower margin products and product material cost increases. Operating costs, exclusive of research and development expense, decreased approximately 9% in 2009, as a result of measures taken in overall operational management of the core business segments. Including research and development expense in total operating expense, overall operating costs increased by approximately 37%. The significant increase in Research and Development expense is a result of costs associated with the planned uranium de-conversion facility. In 2009, Research and Development costs, for that project increased by $2,207,039, to $2,609,834, as compared to $402,795 in 2008. Steve Laflin, President and CEO said, "In 2009, we continued to build our various business segments, make investments into facilities and infrastructure, launch new products, and enter into new agreements we believe will increase our future revenue. Broadly defined, our business strategy is to continue to build our reputation as a leader in the nuclear medicine, and nuclear products industries. We remain dedicated to our core business segments even as we pursue our long range business strategy to construct the nation's first commercial depleted uranium de-conversion and fluorine extraction process facility. Progress on this project in 2009, has been significant. During the year we issued a conceptual design report for the facility, completed an exhaustive site selection process that resulted in our selection of a site location near Hobbs, New Mexico, completed an agreement with the New Mexico Environment Department, and prepared and submitted a license application with environmental report to the Nuclear Regulatory Commission." Laflin went on to note, "Our continued expenditures on this project are contingent upon our ability to raise additional capital. We expect the rate of expenditure on the project to significantly accelerate in 2010 as we begin to incur additional expense for the NRC review of our license application, process the necessary New Mexico state permits, and increase engineering subcontracts to begin formal design and construction planning. This project represents a significant commercial opportunity for the Company and our shareholders. It will continue to require continued significant capital investment by the Company." International Isotopes Inc. Year Ended Dec. 31 -------------------------- 2008 2009 Change $'s Change %---- ---- ---------- --------Sales of Products $5,602,443 $6,122,844 $520,401 9%Gross Profit $2,722,604 $2,049,083 ($673,521) (25%)Total Operating Expense $4,827,985 $6,626,059 $1,798,074 37%Operating Loss Before Other Expense ($2,105,381) ($4,576,976) $2,471,595 117%Other Expense ($61,586) ($56,322) ($5,264) (8%)Net Loss ($2,166,967) ($4,633,298) $2,466,331 114%Net (Loss) Per Common Share ($0.01) ($0.02)Weighted Ave. Sh. Outstanding 276,486,713 290,060,471------------------------------------------------------------------------------------------------------------------------------------------------------------ Visit: www.otc-advisors.com About Options Media Holdings, Inc. Options Media Group Holdings, Inc. is an email services provider for on-demand email marketing to create, send, and track professional and permission-based email marketing campaigns. Additionally, Options Media provides precision direct marketing solutions including email marketing, sms/mobile marketing, sms/keyword marketing, custom lead generation and creative services Options Media provides clients with access to software, hardware, bandwidth, and exclusive domains and IP addresses, as well as the ability to upload and manage subscribers, and review and upload campaigns and track results for a 360-degree full-service customer marketing solution. News Today: Apr 01, 2010 -- Mobile marketing and mobile social media company Options Media Group Holdings Inc (OTCBB:OPMG) announced on Thursday the signing of a letter of intent with PhoneGuard to facilitate its entrance into anti-virus, anti-texting while driving and anti-harassment software market for cell phones and smartphones. No financial details were disclosed. The letter of intent outlines Options Media's acquisition of the North American sublicense from NetQin Tech Co, a mobile security and services provider. Under the terms of the agreement, the company will become the exclusive marketer within the USA and Canada of the PhoneGuard software suite designed to safeguard cellular phones, PDAs and smartphones from attacks by hackers and cyber criminals. ------------------------------------------------------------------------------------------------------------------------------------------------------------ Visit: www.otc-advisors.com About OTC-ADVISORS.COM OTC-ADVISORS.COM is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by OTC-ADVISORS. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed. For additional information: [email protected], www.otc-advisors.com, www.twitter.com/otcadvisors or www.facebook.com/pages/OTC-ADVISORS-LLC/259891872296 ((Comments on this story may be sent to [email protected])) (c) 2010 M2 COMMUNICATIONS |